Journal
SEMINARS IN IMMUNOPATHOLOGY
Volume 34, Issue 3, Pages 365-382Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00281-012-0306-z
Keywords
IgA nephropathy; IgA1; O-glycans; High-resolution mass spectrometry; Measangial cells
Categories
Funding
- National Institutes of Health [DK078244, DK082753, DK083663, DK075868, DK080301, DK077279, DK071802, GM098539]
- IgA Nephropathy Foundation of America
Ask authors/readers for more resources
IgA nephropathy, described in 1968 as IgA-IgG immune-complex disease, is an autoimmune disease. Galactose-deficient IgA1 is recognized by unique autoantibodies, resulting in the formation of pathogenic immune complexes that ultimately induce glomerular injury. Thus, formation of the galactose-deficient IgA1-containing immune complexes is a critical factor in the pathogenesis of IgA nephropathy. Studies of molecular defects of IgA1 can define new biomarkers specific for IgA nephropathy that can be developed into clinical assays to aid in the diagnosis, assessment of prognosis, and monitoring of disease progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available